Intertek to highlight inhalation development at Drug Delivery to the Lungs (DDL) Conference

At the Drug Delivery to the Lungs (DDL) Conference, 6 - 8th December 2017, Edinburgh, UK, discuss your development challenges for pulmonary and nasal drug delivery

The Drug Delivery to the Lungs conference (DDL) is Europe’s premier conference and industry exhibition dedicated to pulmonary and nasal drug delivery. The conference will cover some of the major issues for these product types including new and repurposed drugs, novel formulations and drug combinations, generic inhalers and innovative inhaled treatments based on advances in clinical science and respiratory medicine. Novel inhaler technology, new devices and performance enhancements and novel methods for aerosol measurement and characterisation will also also be discussed.

We are delighted to announce that we are platinum sponsors for the 28th DDL Conference. During DDL, our team of experts will be available to discuss your inhalation product developmentinhalation product testingformulation development or stability testing challenges. Contact our team now to arrange a meeting during the conference

Delivery of drugs to the lungs offers a topical route to treat respiratory disease which is often quicker, more efficacious and requiring less API than if orally or parenterally administered. Delivery to the respiratory tract can also offer a quick and direct route to systemic drug delivery. The range of molecules being considered for delivery by inhalation has recently expanded to include novel drugs for lung infection, combination therapies, biopharmaceuticals and candidates for systemic delivery. For each new inhaled drug development, an excellent understanding of the API, formulation, stability and dose delivery characteristics is essential to ensure a safe and effective medicine.  

Resources:

WHITEPAPER DOWNLOAD: Formulation of Biologics for Inhaled and Nasal Delivery

WEBINAR RECORDING: Stability Programs for Orally Inhaled or Nasal Drug Products

WEBINAR RECORDING: The Fundamentals of Inhaled Product Testing

BROCHURE: Our Orally Inhaled and Nasal Drug Product Development Expertise

 

Learn More about the DDL 2 Conference

The Drug Delivery to the Lungs conference (DDL) is Europe’s premier conference and industry exhibition which is dedicated to pulmonary and nasal drug delivery. DDL provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation. DDL2017 will have five themed sessions that include: Inhaled Therapy in Special Populations, Emerging Therapeutics and Novel Respiratory Medicines, Inhalation Devices and Aerosol Science and Modelling and Simulations in Inhalation Science.

 
Our experts provide integrated OINDP development and testing services for both small molecules and biologics through its centres of excellence across Europe. We provide critical performance and quality testing such as laser particle sizing, aerodynamic particle size distribution (APSD) by impaction (ACI, NGI) and spray pattern/plume geometry. Intertek’s integrated formulation and analytical teams carry out early stage pre-formulation support, solubility screening, drug-excipient compatibility, stability testing and device selection support. For large molecule development, comprehensive protein characterisation services supported by forced degradation and stability monitoring for the protein’s structure and bioactivity throughout formulation and storage can also be provided. Interaction with the device and closure systems are evaluated through comprehensive extractable and leachable testing and toxicological assessments.
Need help or have a question? +44 1763 261648
 

Need help or have a question?

+44 1763 261648
UK:
+44 1763 261648